FOLLICULAR LYMPHOMA

This early-stage study is testing a personalized vaccine designed to help the immune system recognize and attack follicular lymphoma cells. The vaccine is custom-made for each participant using genetic information from their own tumor. Researchers will give the vaccine, sometimes…

This study is testing if adding a low dose of radiation therapy is safe and practical for patients before they receive a CAR-T cell treatment for B-cell lymphoma that has returned or not responded to other therapies. The goal is to see if this combination can improve outcomes for…

This study is testing whether a combination of two drugs, copanlisib and rituximab, can effectively control follicular lymphoma in people who have not yet received treatment. The goal is to see if this drug duo can lead to deep and lasting remissions without using traditional che…

This large, late-stage trial is testing if a shorter course of chemotherapy works as well as the standard, longer treatment for controlling advanced follicular lymphoma when combined with immunotherapy. The study involves over 600 adults with newly diagnosed, high-burden disease.…

This study is testing a new drug called zilovertamab vedotin (MK-2140) for people with several types of advanced B-cell blood cancers that have come back or stopped responding to other treatments. The main goals are to see if the drug is safe and if it can shrink or eliminate the…

This study is testing a new combination of two drugs for people with follicular lymphoma who have not yet received any treatment. The goal is to see how well the drugs work together to shrink or eliminate the cancer. One drug helps the body's immune cells find and kill cancer cel…

This is a first-in-human safety study testing a new, experimental CAR-T cell therapy called CAR19.20.22 in adults with B-cell lymphomas that have returned or not responded to at least two prior treatments. The therapy uses the patient's own immune cells, engineered to attack canc…

This study is testing how well and how safely a combination of two immunotherapy drugs works for people with certain slow-growing lymphomas who have not yet received treatment. The drugs, glofitamab and obinutuzumab, are designed to help the body's own immune system find and atta…

This trial is testing the safety and early effectiveness of a new drug called epcoritamab, given alone or combined with standard treatments, for people with B-cell non-Hodgkin lymphoma. It includes over 500 participants with different types and stages of the disease, including ne…

This study is testing whether combining two drugs—epcoritamab and lenalidomide—works better than either alone for people with follicular lymphoma who haven't had any prior treatment. The goal is to achieve complete remission and control the disease for as long as possible. About …

This study is testing if adding a drug called vorinostat to standard medications can better prevent graft-versus-host disease (GVHD) in children and young adults getting a bone marrow transplant for blood cancers. GVHD is a serious complication where the donor's immune cells atta…

This study aimed to see how well and how safe the pill tazemetostat was for adults whose follicular lymphoma, a type of blood cancer, had come back or stopped responding to treatment. It specifically focused on people whose cancer did not have a certain genetic change called an '…

This study is testing a new oral medication called nemtabrutinib for people with advanced B-cell blood cancers that have come back or stopped responding to other treatments. The main goals are to find a safe and effective dose and to see if the drug can shrink tumors. It is for a…

This trial is testing a drug called epcoritamab, alone or combined with standard treatments, for Japanese adults with B-cell lymphomas that have returned or not responded to prior therapy. The first part finds the safest and most effective dose. The second part treats more people…

This study is testing a two-drug combination for people with certain slow-growing types of B-cell lymphoma who have not yet received treatment. The goal is to see how well the pill ixazomib works when given with the antibody drug rituximab to shrink tumors and control the cancer.…

This study is testing a new type of cell therapy for patients with blood cancers or bone marrow diseases who need a stem cell transplant from a partially matched family donor. The goal is to see if adding specially treated immune cells, called 'veto cells,' can help the donor's c…

This is an early-stage study testing a new antibody drug called IMT-009 in people with advanced solid tumors or lymphomas that have stopped responding to standard treatments. The main goals are to find a safe dose, understand the side effects, and see if the drug helps shrink tum…

This is an early-stage study to find the safest dose of two cancer drugs, copanlisib and nivolumab, when given together. It is for adults with aggressive blood cancers that have transformed from slower-growing types, like Richter's syndrome. The main goal is to see how well patie…

This study is testing whether adding a new drug called tazemetostat to a standard two-drug regimen (bendamustine and rituximab) is safe and effective for adults with high-tumor-burden follicular lymphoma who have not had prior treatment. The main goals are to see if the three-dru…

This large, late-stage study is testing if adding a new drug, tafasitamab, to a standard two-drug regimen (lenalidomide + rituximab) works better for controlling two types of slow-growing lymphoma that have returned or stopped responding to prior treatment. It involves 654 patien…

This study is testing whether giving a pneumonia vaccine before and after a powerful cancer treatment called CAR T cell therapy can better protect patients from serious infections. It involves 26 adults with certain types of B-cell lymphoma who are scheduled for CAR T therapy. Th…

This study aims to create a tool that can better predict which patients with follicular lymphoma will remain progression-free two years after their initial treatment. Researchers will analyze existing tumor samples and medical records from 370 patients to identify patterns linked…